Video Latest - ecancer

Comment on RESONATE2 and CLL115 trials

Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK

29 Apr 2016

Clinical cases employing novel agents in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Centre, New York, USA

29 Apr 2016

Current trials in chronic lymphocytic leukaemia

Dr George Follows - Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

29 Apr 2016

Chronic lymphocytic leukaemia: Transition to a new era

Prof Stephen Mulligan - Royal North Shore Hospital, Australia

29 Apr 2016

Ibrutinib as a frontline therapy in RESONATE2 trials for CLL

Prof Jan Burger, MD Anderson Cancer Center, Texas, USA

29 Apr 2016

The role of the microenvironment and novel therapies in CLL

Prof Jan Burger - MD Anderson Cancer Center, Texas, USA

29 Apr 2016

Editor's Choice for April 2016

Prof Gordon McVie - ecancer Editor

29 Apr 2016

Drugging “undruggable” transcription factor drivers in cancer

Dr John Bushweller - Unviersity of Virgina, Virginia, USA

28 Apr 2016

Pembrolizumab yielded durable responses in patients with advanced Merkel cell carcinoma

Dr Paul Nghiem - University of Washington, Seattle, USA

28 Apr 2016

Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer

Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA

28 Apr 2016

Elucidation and pharmacological targeting of tumour checkpoint dependencies

Dr Andrea Califano - Colombia University Medical Centre, New York, USA

28 Apr 2016

Identifying myeloid-driven biologies

Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA

28 Apr 2016

Video